Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

241. A comparison of observational studies and controlled trials of heparin in ulcerative colitis

A comparison of observational studies and controlled trials of heparin in ulcerative colitis A comparison of observational studies and controlled trials of heparin in ulcerative colitis A comparison of observational studies and controlled trials of heparin in ulcerative colitis Malhotra S, Kondal A, Shafiq N, Sidhu S, Bhasin D K, Pandhi P CRD summary This review assessed the effects of heparin in ulcerative colitis and compared findings from observational and controlled studies. The authors (...) concluded that although findings from controlled and observational studies differed, randomised controlled trials provided no evidence of a benefit with heparin. The limited search and limited evidence from a few small studies make it difficult to assess the reliability of the authors' conclusions. Authors' objectives To assess the effects of heparin in patients with ulcerative colitis and to compare findings from observational and controlled studies. Searching Studies were identified through a search

DARE.2004

242. Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months

Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months Conti S, Guercini F, Iorio A CRD summary This review (...) concluded that, compared with oral anticoagulants, long-term treatment (at least 3 months) with low molecular weight heparin for the prevention of recurrent venous thromboembolism does not reduce cancer mortality. The results should be treated with caution because they were derived from studies which the authors acknowledged had significant clinical differences, and which were of uncertain quality. In addition, most did not have cancer mortality as a primary end point. Authors' objectives To determine

DARE.2004

243. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials

Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials Quinlan (...) D J, McQuillan A, Eikelboom J W CRD summary This review reported that fixed-dose low molecular weight heparin appeared to be as effective and safe as dose-adjusted intravenous unfractionated heparin for the initial treatment of nonmassive pulmonary embolism. The authors also found no differences between the treatments in major and minor bleeding, and all-cause mortality. The review was well conducted and the findings are likely to be reliable. Authors' objectives To compare the efficacy

DARE.2004

244. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials

Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials Lim W, Cook D J, Crowther M A CRD summary (...) This review compared the safety and efficacy of low molecular weight heparin (LMWH) with unfractionated heparin (UFH) for preventing thrombosis of the extracorporeal dialysis circuit. The authors concluded that there is limited evidence that LMWH is as safe and effective as UFH, and that larger higher-quality randomised controlled trials are required. The limitations of the evidence are reflected in the appropriately tentative conclusions. Authors' objectives To investigate the safety and efficacy

DARE.2004

245. Treatment of heparin-induced thrombocytopenia: a critical review

Treatment of heparin-induced thrombocytopenia: a critical review Treatment of heparin-induced thrombocytopenia: a critical review Treatment of heparin-induced thrombocytopenia: a critical review Hirsh J, Heddle N, Kelton J G CRD summary This review assessed the effects of replacing heparin with new anticoagulants in patients with heparin-induced thrombocytopenia. The authors' conclusions appear to be that lepirudin and argatroban are effective anticoagulants, but the evidence was limited (...) and further research is required. The authors correctly acknowledged the limitations of evidence from the included observational studies. Authors' objectives To assess the effects of replacing heparin with new anticoagulants in patients with heparin-induced thrombocytopenia (HIT). Searching MEDLINE (via PubMed), OLDMEDLINE, LocatorPlus, MedlinePlus, DIRLINE, AIDS Meetings, Health Service Research Meetings, Space Life Science Meetings and HSRProj, all via the Gateway search engine, and EMBASE were searched

DARE.2004

246. Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins: a meta-analysis

Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins: a meta-analysis Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins: a meta-analysis Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins (...) weaknesses in the included studies suggest that the results should be interpreted cautiously. Authors' objectives To evaluate the correlation between thrombus regression assessed by venography after stopping heparin administration and the incidence of recurrent venous thromboembolism (VTE). Searching MEDLINE, the Cochrane CENTRAL Register, Excerpta Medica and Adis Clinical Trials Insight were searched from January 1985 to May 2003; the search terms were reported. No language restriction was applied

DARE.2004

247. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial

Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial Economic evaluation of bivalirudin with provisional (...) glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial Cohen D J, Lincoff A M, Lavelle T A, Chen H L, Bakhai A, Berezin R H, Jackman D, Sarembock I J, Topol E J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

NHS Economic Evaluation Database.2004

248. Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation

Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous (...) -infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation Fanikos J, Tsilimingras K, Kucher N, Rosen A B, Hieblinger M D, Goldhaber S Z Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health

NHS Economic Evaluation Database.2004

249. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients

Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients McGarry L J, Thompson D, Weinstein M C, Goldhaber S Z Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three prophylactic strategies for the prevention of venous thromboembolism (VTE) were compared in acutely ill medical inpatients. Strategy 1 was enoxaparin, a low molecular weight heparin (LMWH), at a dose

NHS Economic Evaluation Database.2004

250. Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy

Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy Costs and clinical outcomes associated with low-molecular-weight heparin vs unfractionated heparin for perioperative bridging (...) in patients receiving long-term oral anticoagulant therapy Spyropoulos A C, Frost F J, Hurley J S, Roberts M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of low molecular weight heparin (LMWH) during the perioperative period

NHS Economic Evaluation Database.2004

251. Cost savings and effectiveness of outpatient treatment with low molecular weight heparin of deep vein thrombosis in a community hospital

Cost savings and effectiveness of outpatient treatment with low molecular weight heparin of deep vein thrombosis in a community hospital Cost savings and effectiveness of outpatient treatment with low molecular weight heparin of deep vein thrombosis in a community hospital Cost savings and effectiveness of outpatient treatment with low molecular weight heparin of deep vein thrombosis in a community hospital Lee M, Pao D, Hsu T, Sonderskov A Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined a home care programme using low molecular weight heparin (LMWH), namely tinzaparin, for the treatment of uncomplicated deep vein thrombosis (DVT). Patients receiving home care were sent home on tinzaparin

NHS Economic Evaluation Database.2004

252. Heparin therapy of recurrent spontaneous abortion related to antiphospholipid syndrome

Heparin therapy of recurrent spontaneous abortion related to antiphospholipid syndrome Heparin therapy of recurrent spontaneous abortion related to antiphospholipid syndrome Heparin therapy of recurrent spontaneous abortion related to antiphospholipid syndrome Garcia Marti S, Pichon Riviere A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Garcia Marti S, Pichon Riviere A. Heparin therapy of recurrent spontaneous abortion related to antiphospholipid syndrome. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2004 Authors' objectives The aim of this study was to assess the effectiveness of heparin therapy of recurrent spontaneous abortion related to antiphospholipid syndrome. Authors' conclusions In this group of patients, the risk of having a spontaneous abortion without therapy

Health Technology Assessment (HTA) Database.2004

253. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials

Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials Wan S, Quinlan DJ, Agnelli G, Eikelboom JW CRD summary This review concluded that evidence (...) for a benefit of thrombolytic therapy compared with heparin for the initial treatment of patients with acute pulmonary embolism was lacking; there may be a benefit in high-risk patients. Given the limitations of the evidence available, the reliability and applicability of the overall estimates and conclusions are uncertain. Authors' objectives To compare the efficacy and safety of thrombolytic therapy with heparin in patients with acute pulmonary embolism (blood clot in the pulmonary artery). Searching

DARE.2004

254. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. 15238590 2004 07 07 2004 07 13 2016 10 17 1538-3598 292 1 2004 Jul 07 JAMA JAMA Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized (...) trial. 45-54 Enoxaparin has demonstrated advantages over unfractionated heparin in low- to moderate-risk patients with non-ST-segment elevation acute coronary syndromes (ACS) treated with a conservative strategy. To compare the outcomes of patients treated with enoxaparin vs unfractionated heparin and to define the role of enoxaparin in patients with non-ST-segment elevation ACS at high risk for ischemic cardiac complications managed with an early invasive approach. The Superior Yield of the New

JAMA2004

255. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. 15238591 2004 07 07 2004 07 13 2016 10 17 1538-3598 292 1 2004 Jul 07 JAMA JAMA Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. 55-64 Enoxaparin (...) or the combination of glycoprotein IIb/IIIa inhibitor tirofiban with unfractionated heparin independently have shown superior efficacy over unfractionated heparin alone in patients with non-ST-elevation acute coronary syndromes (ACS). It is not clear if combining enoxaparin with glycoprotein IIb/IIIa inhibitors is as safe or as effective as the current standard combination of unfractionated heparin with glycoprotein IIb/IIIa inhibitors. To assess efficacy and safety of the combination of enoxaparin and tirofiban

JAMA2004

256. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.

Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. 15238596 2004 07 07 2004 07 13 2016 10 17 1538-3598 292 1 2004 Jul 07 JAMA JAMA Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. 89-96 (...) Antithrombin therapy has become a guidelines-recommended standard of care in the treatment of acute coronary syndromes (ACS), but recent trials comparing use of enoxaparin and unfractionated heparin in ACS have yielded less robust efficacy and safety results than have earlier trials of these antithrombin therapies. To systematically evaluate the end points of all-cause death and nonfatal myocardial infarction (MI), transfusion, and major bleeding observed in the 6 randomized controlled trials comparing

JAMA2004

257. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.

Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. 15304466 2004 08 12 2004 08 16 2016 11 24 1538-3598 292 6 2004 Aug 11 JAMA JAMA Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized (...) trial. 696-703 In the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial, bivalirudin with provisional glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition was found to be noninferior to heparin plus planned Gp IIb/IIIa blockade in the prevention of acute ischemic end points and was associated with significantly less bleeding by 30 days after percutaneous coronary intervention (PCI). To determine whether the efficacy of bivalirudin remains comparable

JAMA2004

258. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention.

Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. CONTEXT: Low-molecular-weight heparins (LMWHs) possess several potential pharmacological advantages over unfractionated heparin as an antithrombotic agent. OBJECTIVE: To systematically summarize the clinical data on the efficacy and safety of LMWHs compared with unfractionated heparin across the spectrum of acute coronary syndromes (ACSs), and as an adjunct (...) to percutaneous coronary intervention (PCI). DATA SOURCES: We searched MEDLINE for articles from 1990 to 2002 using the index terms heparin, enoxaparin, dalteparin, nadroparin, tinzaparin, low molecular weight heparin, myocardial infarction, unstable angina, coronary angiography, coronary angioplasty, thrombolytic therapy, reperfusion, and drug therapy, combination. Additional data sources included bibliographies of articles identified on MEDLINE, inquiry of experts and pharmaceutical companies, and data

JAMA2003

259. [Low molecular weight heparins versus traditional heparins in thromboembolic diseases]

[Low molecular weight heparins versus traditional heparins in thromboembolic diseases] Heparinas de bajo peso molecular versus clasicas en enfermedad tromboembolica [Low molecular weight heparins versus traditional heparins in thromboembolic diseases] Heparinas de bajo peso molecular versus clasicas en enfermedad tromboembolica [Low molecular weight heparins versus traditional heparins in thromboembolic diseases] Mujika N, Bermejo M C, Capellan J F, Dorronsoro S Citation Mujika N, Bermejo M C (...) , Capellan J F, Dorronsoro S. Heparinas de bajo peso molecular versus clasicas en enfermedad tromboembolica. [Low molecular weight heparins versus traditional heparins in thromboembolic diseases] Vitoria-Gasteiz: Basque Office for Health Technology Assessment (OSTEBA). D-02-08. 2003 Authors' objectives

This review aims to determine the safety and efficiency of low molecular weight heparins (LMWH) in comparison with non-fractionated heparins (NFH) in the treatment and preparation

Health Technology Assessment (HTA) Database.2003

260. Low molecular weight heparin in vein thrombosis

Low molecular weight heparin in vein thrombosis Low molecular weight heparin in vein thrombosis Low molecular weight heparin in vein thrombosis Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D (...) , Regueiro A, Garcia Marti S. Low molecular weight heparin in vein thrombosis. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2003 Authors' objectives The objective of this evaluation is to analyze the efficacy of low molecular weight heparin (LMWH) compared with dicumarinic drugs in the prevention and treatment of deep vein thrombosis an pulmonary embolism. Authors' conclusions At present, its use could be justified as initial anticoagulation therapy, both

Health Technology Assessment (HTA) Database.2003